These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 21847523

  • 1. Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis.
    Crespo O, Kang SC, Daneman R, Lindstrom TM, Ho PP, Sobel RA, Steinman L, Robinson WH.
    J Clin Immunol; 2011 Dec; 31(6):1010-20. PubMed ID: 21847523
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of imatinib mesylate in mouse models of multiple sclerosis and in vitro determinants.
    Azizi G, Haidari MR, Khorramizadeh M, Naddafi F, Sadria R, Javanbakht MH, Sedaghat R, Tofighi Zavareh F, Mirshafiey A.
    Iran J Allergy Asthma Immunol; 2014 Jun; 13(3):198-206. PubMed ID: 24659124
    [Abstract] [Full Text] [Related]

  • 8. Sorafenib: muscle wasting.
    Prescrire Int; 2011 Dec; 20(122):296-7. PubMed ID: 22216546
    [Abstract] [Full Text] [Related]

  • 9. Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer.
    Toubert ME, Vercellino L, Faugeron I, Lussato D, Hindie E, Bousquet G.
    Thyroid; 2011 Apr; 21(4):451-4. PubMed ID: 21385075
    [Abstract] [Full Text] [Related]

  • 10. Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.
    Hu S, Niu H, Minkin P, Orwick S, Shimada A, Inaba H, Dahl GV, Rubnitz J, Baker SD.
    Mol Cancer Ther; 2008 May; 7(5):1110-20. PubMed ID: 18483300
    [Abstract] [Full Text] [Related]

  • 11. [Management of hypothyroidism secondary to tyrosine kinase inhibitors: description of treatment in three distinct clinical settings].
    Pérez López G, Carrasco De La Fuente M, Menacho Román M, González Albarrán O, Cano Megías M.
    Endocrinol Nutr; 2011 Feb; 58(2):94-6. PubMed ID: 21333617
    [No Abstract] [Full Text] [Related]

  • 12. Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.
    Kitagawa D, Gouda M, Kirii Y, Sugiyama N, Ishihama Y, Fujii I, Narumi Y, Akita K, Yokota K.
    J Biochem; 2012 Jan; 151(1):47-55. PubMed ID: 21880693
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cutaneous side-effects of kinase inhibitors and blocking antibodies.
    Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP, Le Chevalier T.
    Lancet Oncol; 2005 Jul; 6(7):491-500. PubMed ID: 15992698
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation.
    Zhao W, Gu YH, Song R, Qu BQ, Xu Q.
    Leukemia; 2008 Jun; 22(6):1226-33. PubMed ID: 18337760
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.